Education
About Us
Working with TipRanks
Follow Us
Pyxis Oncology (PYXS)
NASDAQ:PYXS
PYXS Analyst Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
PYXS Stock 12 Month Forecast
Average Price Target
$6.50
▲(446.22% Upside)
| Highest Price Target$8.00 | Average Price Target$6.50 | Lowest Price Target$5.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
Reiterated
12/20/24
LifeSci Capital
Reiterated
12/20/24
RBC Capital
Reiterated
12/19/24
William Blair
―
Hold
―
Downgraded
11/21/24
Pyxis Oncology downgraded to Market Perform from Outperform at William BlairPyxis Oncology downgraded to Market Perform from Outperform at William Blair
Stifel Nicolaus
$10
Buy
740.34%
Upside
Reiterated
11/21/24
Stifel Nicolaus Remains a Buy on Pyxis Oncology (PYXS)
Leerink Partners
$12
Buy
908.40%
Upside
Reiterated
11/21/24
We are encouraged by the early clinical proof-of- concept (PoC) for PYX-201, Pyxis’s (PYXS, OP) first-in-class, stroma-targeted (anti-EDB-FN) antibody drug conjugate (ADC). In our view, the company has proven that targeting an ADC to the tumor microenvironment (TME) has relevant clinical value, with pharmacokinetic and toxicity / efficacy profiles that are distinctive from tumor-targeting ADCs. This is a big deal, especially in a sea of “me-too” ADCs. We also recognize the signal is early and there are many lingering uncertainties for the program. This includes a more uncertain development path with an ADC that may be most effective in combination or require an algorithm-type of companion diagnostic, for example.
Stephens
$13
Buy
992.44%
Upside
Initiated
11/07/24
Pyxis Oncology initiated with an Overweight at StephensPyxis Oncology initiated with an Overweight at Stephens
Jefferies
$10
Buy
740.34%
Upside
Initiated
05/07/24
Pyxis Oncology assumed with a Buy at JefferiesPyxis Oncology assumed with a Buy at Jefferies
Best Analysts Covering Pyxis Oncology
Which Analyst Should I Follow If I Want to Buy PYXS and Sell After:
1 Month
xxx
Success Rate
4/7 ratings generated profit
Average Return
-3.09%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of -3.09% per trade.
3 Months
xxx
Success Rate
3/9 ratings generated profit
Average Return
-4.92%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -4.92% per trade.
1 Year
Success Rate
4/9 ratings generated profit
Average Return
-1.91%
reiterated a buy rating 2 months ago
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -1.91% per trade.
2 Years
xxx
Success Rate
0/9 ratings generated profit
Average Return
-55.78%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -55.78% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
PYXS Analyst Recommendation Trends
Rating
Aug 24
Sep 24
Oct 24
Nov 24
Dec 24
Strong Buy
6
4
4
10
11
Buy
4
3
3
5
5
Hold
0
0
0
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
7
7
17
18
Each month's total comprises the sum of three months' worth of ratings.
PYXS Financial Forecast
PYXS Stock Forecast FAQ
What is PYXS’s average 12-month price target, according to analysts?
Based on analyst ratings, Pyxis Oncology’s 12-month average price target is $6.50.
What is PYXS’s upside potential, based on the analysts’ average price target?
Pyxis Oncology has 446.22% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PYXS a Buy, Sell or Hold?
Pyxis Oncology has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
What is Pyxis Oncology’s price target?
The average price target for Pyxis Oncology is $6.50. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $8.00 ,the lowest forecast is $5.00. The average price target represents 446.22% Increase from the current price of $1.19.
The highest analyst price target is $8.00 ,the lowest forecast is $5.00. The average price target represents 446.22% Increase from the current price of $1.19.
What do analysts say about Pyxis Oncology?
Pyxis Oncology’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of PYXS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.